Livzon Pharmaceutical Group's (HKG:1513, SHE:000513) net profit attributable to shareholders rose 5.5% to 2.06 billion yuan from 1.95 billion yuan a year earlier, according to a Hong Kong Stock Exchange disclosure on Wednesday.
Earnings per share rose 6.7% year on year to 2.24 yuan from 2.10 yuan.
The Chinese pharmaceutical company's operating income fell 5% to 11.8 billion yuan from 12.4 billion yuan in the preceding year, the disclosure said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。